Composecure (NYSE:GPGI) Trading Up 4.7% After Insider Buying Activity

Composecure (NYSE:GPGI) saw its shares trade up 4.7% after three insiders purchased additional shares in the company on March 17th. Thomas R. Knott, John D. Cote, and Kurt Schoen collectively acquired shares worth over $900,000. Despite this insider buying activity and the stock's rise, Weiss Ratings initiated a "sell" rating, and MarketBeat shows a consensus "Sell" rating for Composecure.

Original reporting
MarketBeat · MarketBeat
Published Mar 18, 2026, 3:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 18, 2026, 3:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$GPGI
Neutral
medium confidence
Mentioned
$GPGI
Relevance
6/10
AlphAI data visualization · based on MarketBeat
Decision brief

The 30-second read

$GPGINeutralMed
01

Why it matters

However, Weiss Ratings has issued a 'sell' rating, indicating potential underlying issues or overvaluation.

02

Market read

The news has moderate relevance for traders focusing on healthcare stocks or short-term trading strategies.

03

What to watch

Potential upcoming negative news or earnings report that could offset insider optimism.

Relevance 6/10Timing: short-term (next few days)

Background

Composecure (GPGI) has seen recent insider buying activity, which often signals confidence from management.

Company-level read

Ticker impact

$GPGINeutralMedium confidence
Context

The news highlights insider buying activity and a recent stock price increase, which can influence trading decisions.

Expected impact

Potential short-term upward movement, but long-term outlook remains uncertain.

Evidence & confidence

Insider buying suggests confidence, but negative analyst ratings and consensus sell rating temper optimism.

Market effects

Limited sector impact; the company's sector does not show significant movement based on this news.

Minimal regional effects; the news is company-specific.

Negligible

Counterpoint

Despite insider buying, the negative analyst ratings suggest caution; the stock may be overreacting to insider activity.

Key entities

  • Composecure

    A healthcare technology company listed on NYSE.

Related articles

$GPGIMed

GPGI 3Q 2026: Revenue $0, EPS $0.26 — 10-Q Summary

GPGI reported 3Q 2026 revenue of $0 but net income of $76M, up 143.5% YoY, driven by equity-method investment earnings. GPGI Holdings sales rose 321.5% YoY to $509.6M, with Husky and CompoSecure contributing to growth. Adjusted EBITDA for CompoSecure and Husky combined was $150.0M, up from $49.8M YoY.

$GPGIHighAI 8/10

GPGI (GPGI) Q3 2026 Earnings Call Transcript

GPGI reported Q3 2026 earnings with sales up 5% YoY to $509.6M and EBITDA up 7% to $146.3M. The company expects low single-digit revenue growth and high single-digit EBITDA growth in Q4. Full-year 2026 guidance was adjusted, with revenue expected to meet prior forecasts but EBITDA and free cash flow lowered due to Husky's delayed cost actions and mix issues. GPGI aims for long-term growth with mid- to high single-digit annual organic growth and double-digit EBITDA growth.

$GPGILow

GPGI Third Quarter 2026 Earnings Presentation November 5, 2026 TM

GPGI, Inc. (GPGI) filed an SEC Form 8-K — Results of Operations and Financial Condition. GPGI Third Quarter 2026 Earnings Presentation November 5, 2026 TM Disclaimer 2 Caution Concerning Forward-Looking Statements: This presentation, and other statements that GPGI, Inc. (“GPGI,” “we,” “us” or the “Company”) may make in connection therewith, contains forward-looking s

$GPGIMedAI 8/10

GPGI (GPGI) Q2 2026 Earnings Call Transcript

GPGI, Inc. (GPGI) reported Q2 2026 results on an earnings call. Pro forma adjusted net sales were $473.2 million, down 4%, and pro forma adjusted EBITDA was $113.9 million, down 13%, with margin at 24.1%. GAAP net income was $50.3 million. FY2026 guidance: revenue $1.95B-$2.1B, adjusted EBITDA $550M-$610M, and free cash flow $275M-$325M.

$GPGIMed

1 News Release GPGI Reports Second Quarter 2026 Results

GPGI, Inc. (GPGI) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 News Release GPGI Reports Second Quarter 2026 Results ▪ CompoSecure delivers record ROS-enabled results ▪ Husky performance in line with expectations ▪ ROS deployment accelerating at both companies ▪ Progress across the platform – reiterating full year 2026 guidance Second Quar